These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

452 related articles for article (PubMed ID: 27571886)

  • 1. Inhibition of glioblastoma tumorspheres by combined treatment with 2-deoxyglucose and metformin.
    Kim EH; Lee JH; Oh Y; Koh I; Shim JK; Park J; Choi J; Yun M; Jeon JY; Huh YM; Chang JH; Kim SH; Kim KS; Cheong JH; Kim P; Kang SG
    Neuro Oncol; 2017 Feb; 19(2):197-207. PubMed ID: 27571886
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regulation of bioenergetics through dual inhibition of aldehyde dehydrogenase and mitochondrial complex I suppresses glioblastoma tumorspheres.
    Park J; Shim JK; Kang JH; Choi J; Chang JH; Kim SY; Kang SG
    Neuro Oncol; 2018 Jun; 20(7):954-965. PubMed ID: 29294080
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel biguanide (IM1761065) inhibits bioenergetics of glioblastoma tumorspheres.
    Roh TH; Lee JH; Kim SJ; Shim JK; Park J; Yoon SJ; Teo WY; Kim SH; Chang JH; Kang SG
    J Neurooncol; 2022 Jan; 156(1):139-151. PubMed ID: 34811601
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dual inhibition of tumor energy pathway by 2-deoxyglucose and metformin is effective against a broad spectrum of preclinical cancer models.
    Cheong JH; Park ES; Liang J; Dennison JB; Tsavachidou D; Nguyen-Charles C; Wa Cheng K; Hall H; Zhang D; Lu Y; Ravoori M; Kundra V; Ajani J; Lee JS; Ki Hong W; Mills GB
    Mol Cancer Ther; 2011 Dec; 10(12):2350-62. PubMed ID: 21992792
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The contribution of ketone bodies to glycolytic inhibition for the treatment of adult and pediatric glioblastoma.
    Vallejo FA; Shah SS; de Cordoba N; Walters WM; Prince J; Khatib Z; Komotar RJ; Vanni S; Graham RM
    J Neurooncol; 2020 Apr; 147(2):317-326. PubMed ID: 32096068
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibiting stemness and invasive properties of glioblastoma tumorsphere by combined treatment with temozolomide and a newly designed biguanide (HL156A).
    Choi J; Lee JH; Koh I; Shim JK; Park J; Jeon JY; Yun M; Kim SH; Yook JI; Kim EH; Chang JH; Kim SH; Huh YM; Lee SJ; Pollak M; Kim P; Kang SG; Cheong JH
    Oncotarget; 2016 Oct; 7(40):65643-65659. PubMed ID: 27582539
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined effects of niclosamide and temozolomide against human glioblastoma tumorspheres.
    Oh HC; Shim JK; Park J; Lee JH; Choi RJ; Kim NH; Kim HS; Moon JH; Kim EH; Chang JH; Yook JI; Kang SG
    J Cancer Res Clin Oncol; 2020 Nov; 146(11):2817-2828. PubMed ID: 32712753
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined treatment with 2'-hydroxycinnamaldehyde and temozolomide suppresses glioblastoma tumorspheres by decreasing stemness and invasiveness.
    Jeong H; Park J; Shim JK; Lee JE; Kim NH; Kim HS; Chang JH; Yook JI; Kang SG
    J Neurooncol; 2019 May; 143(1):69-77. PubMed ID: 30887242
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metformin treatment reduces temozolomide resistance of glioblastoma cells.
    Yang SH; Li S; Lu G; Xue H; Kim DH; Zhu JJ; Liu Y
    Oncotarget; 2016 Nov; 7(48):78787-78803. PubMed ID: 27791206
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Co-treatment of breast cancer cells with pharmacologic doses of 2-deoxy-D-glucose and metformin: Starving tumors.
    Wokoun U; Hellriegel M; Emons G; Gründker C
    Oncol Rep; 2017 Apr; 37(4):2418-2424. PubMed ID: 28350075
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting P-glycoprotein expression and cancer cell energy metabolism: combination of metformin and 2-deoxyglucose reverses the multidrug resistance of K562/Dox cells to doxorubicin.
    Xue C; Wang C; Liu Q; Meng Q; Sun H; Huo X; Ma X; Liu Z; Ma X; Peng J; Liu K
    Tumour Biol; 2016 Jul; 37(7):8587-97. PubMed ID: 26733176
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metformin and temozolomide act synergistically to inhibit growth of glioma cells and glioma stem cells in vitro and in vivo.
    Yu Z; Zhao G; Xie G; Zhao L; Chen Y; Yu H; Zhang Z; Li C; Li Y
    Oncotarget; 2015 Oct; 6(32):32930-43. PubMed ID: 26431379
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anticancer drug candidate CBL0137, which inhibits histone chaperone FACT, is efficacious in preclinical orthotopic models of temozolomide-responsive and -resistant glioblastoma.
    Barone TA; Burkhart CA; Safina A; Haderski G; Gurova KV; Purmal AA; Gudkov AV; Plunkett RJ
    Neuro Oncol; 2017 Feb; 19(2):186-196. PubMed ID: 27370399
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The combination of metformin and 2-deoxyglucose inhibits autophagy and induces AMPK-dependent apoptosis in prostate cancer cells.
    Ben Sahra I; Tanti JF; Bost F
    Autophagy; 2010 Jul; 6(5):670-1. PubMed ID: 20559023
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Metabolic Inhibitory Cocktail for Grave Cancers: Metformin, Pioglitazone and Lithium Combination in Treatment of Pancreatic Cancer and Glioblastoma Multiforme.
    Elmaci İ; Altinoz MA
    Biochem Genet; 2016 Oct; 54(5):573-618. PubMed ID: 27377891
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting cancer cell metabolism: the combination of metformin and 2-deoxyglucose induces p53-dependent apoptosis in prostate cancer cells.
    Ben Sahra I; Laurent K; Giuliano S; Larbret F; Ponzio G; Gounon P; Le Marchand-Brustel Y; Giorgetti-Peraldi S; Cormont M; Bertolotto C; Deckert M; Auberger P; Tanti JF; Bost F
    Cancer Res; 2010 Mar; 70(6):2465-75. PubMed ID: 20215500
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synergistic effect of MEK inhibitor and metformin combination in low grade serous ovarian cancer.
    Mert I; Chhina J; Allo G; Dai J; Seward S; Carey MS; Llaurado M; Giri S; Rattan R; Munkarah AR
    Gynecol Oncol; 2017 Aug; 146(2):319-326. PubMed ID: 28545687
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dual mTORC1/2 blockade inhibits glioblastoma brain tumor initiating cells in vitro and in vivo and synergizes with temozolomide to increase orthotopic xenograft survival.
    Luchman HA; Stechishin OD; Nguyen SA; Lun XQ; Cairncross JG; Weiss S
    Clin Cancer Res; 2014 Nov; 20(22):5756-67. PubMed ID: 25316808
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biological basis and clinical study of glycogen synthase kinase- 3β-targeted therapy by drug repositioning for glioblastoma.
    Furuta T; Sabit H; Dong Y; Miyashita K; Kinoshita M; Uchiyama N; Hayashi Y; Hayashi Y; Minamoto T; Nakada M
    Oncotarget; 2017 Apr; 8(14):22811-22824. PubMed ID: 28423558
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel Targeting of Transcription and Metabolism in Glioblastoma.
    Su YT; Chen R; Wang H; Song H; Zhang Q; Chen LY; Lappin H; Vasconcelos G; Lita A; Maric D; Li A; Celiku O; Zhang W; Meetze K; Estok T; Larion M; Abu-Asab M; Zhuang Z; Yang C; Gilbert MR; Wu J
    Clin Cancer Res; 2018 Mar; 24(5):1124-1137. PubMed ID: 29254993
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 23.